Verge Genomics is a biotechnology company focused on accelerating neurodegenerative disease drug discovery by leveraging artificial intelligence and human genomics data.
Its core technology is a proprietary AI and machine learning platform that integrates and analyzes large-scale human genomics data to identify new drug targets and predict candidate compounds.
The company mainly focuses on neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
According to public information, its business model has shifted toward partnerships and licensing its AI drug discovery platform.
Its ALS candidate VRG50635 had entered clinical trials, but according to a December 2025 announcement, the Phase 1b trial did not meet efficacy endpoints and was terminated.
The platform integrates and analyzes large-scale human genomics data, including patient genomes and gene expression data, to drive its AI models.
Public information shows Eli Lilly is an investor and partner.
As a biotech company, the platform is typically provided through research collaborations and licensing; specific terms should be obtained directly from the company.

Lever AI is a modern AI-powered recruitment software platform that combines an applicant tracking system (ATS) with candidate relationship management (CRM) capabilities. It helps hiring teams streamline recruitment, boost efficiency, and improve the candidate experience through automation, intelligent screening, and data analytics.

Atomwise AI leverages its proprietary AtomNet® platform to accelerate small-molecule drug discovery with deep convolutional neural networks, enabling efficient virtual screening and optimization of a library of over 16 billion compounds.